Comparison of Erlotinib vs. Osimertinib for Advanced or Metastatic EGFR Mutation-Positive Non-Small-Cell Lung Cancer Without Prior Treatment: A Network Meta-Analysis.
- DOI
- 10.3390/cancers17111895
- Published
- 2025 Jun 5
- Container
- Cancers
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.3390/cancers17111895,
title = {Comparison of Erlotinib vs. Osimertinib for Advanced or Metastatic EGFR Mutation-Positive Non-Small-Cell Lung Cancer Without Prior Treatment: A Network Meta-Analysis.},
author = {Runzer-Colmenares FM and Ruiz R and Maco L and Maldonado M and Puma-Villanueva L and Galvez-Nino M and Aliaga C and Benites-Zapata VA and Diaz-Arocutipa C and Mas L and Urrunaga-Pastor D},
year = {2025},
journal = {Cancers},
doi = {10.3390/cancers17111895},
url = {https://doi.org/10.3390/cancers17111895}
}RIS
TY - JOUR TI - Comparison of Erlotinib vs. Osimertinib for Advanced or Metastatic EGFR Mutation-Positive Non-Small-Cell Lung Cancer Without Prior Treatment: A Network Meta-Analysis. AU - Runzer-Colmenares FM AU - Ruiz R AU - Maco L AU - Maldonado M AU - Puma-Villanueva L AU - Galvez-Nino M AU - Aliaga C AU - Benites-Zapata VA AU - Diaz-Arocutipa C AU - Mas L AU - Urrunaga-Pastor D PY - 2025 JO - Cancers DO - 10.3390/cancers17111895 UR - https://doi.org/10.3390/cancers17111895 ER -
APA
FM, R., R, R., L, M., M, M., L, P., M, G., C, A., VA, B., C, D., L, M., & D, U. (2025). Comparison of Erlotinib vs. Osimertinib for Advanced or Metastatic EGFR Mutation-Positive Non-Small-Cell Lung Cancer Without Prior Treatment: A Network Meta-Analysis.. Cancers. https://doi.org/10.3390/cancers17111895
Source records
- pubmed · retrieved 2026-09-26T22:57:08.100Z
- europe-pmc · retrieved 2026-09-26T22:57:08.109Z